<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): July 6, 2000
ViroPharma Incorporated
-----------------------
(Exact name of issuer as specified in charter)
DELAWARE 0-021699 23-2789550
(State or Other Jurisdiction (Commission (I.R.S. Employer
of Incorporation or file Identification
Organization) number) Number)
405 EAGLEVIEW BOULEVARD
EXTON, PENNSYLVANIA 19341
(Address of principal executive offices)
(610) 458-7300
(Registrant's telephone number, including area code)
<PAGE>
Item 5 - Other Events.
As is more fully described in the attached press release that is
incorporated herein by reference, on July 6, 2000, ViroPharma Incorporated
("ViroPharma") announced the appointment of Dennis Purcell to its board of
directors as a Class III director to serve until the 2002 annual meeting of
shareholders. Mr. Purcell will also serve on the audit committee. Mr. Purcell
replaces Ann H. Lamont on the ViroPharma board of directors.
Item 7 - Financial Statements, Pro Forma Financial Information and Exhibits.
(c) Exhibits
Exhibit No. Description
----------- -----------
99 ViroPharma Incorporated Press Release dated July 6,
2000
<PAGE>
Signatures
Pursuant to the requirements of the Securities and Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned, hereunto duly authorized.
ViroPharma Incorporated
Date: July 7, 2000 By: /s/ Claude H. Nash
------------------
Claude H. Nash
President and Chief Executive Officer
<PAGE>
Index to Exhibits
Exhibit No. Description
----------- -----------
99 ViroPharma Incorporated Press Release dated July 6, 2000
